Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
PURPOSE: To compare the progression-free and overall survival in small-volume residual ovarian cancer after treatment with intravenous (IV) cisplatin and paclitaxel or an experimental regimen of IV carboplatin followed by IV paclitaxel and intraperitoneal cisplatin. PATIENTS AND METHODS: Patients were randomized to receive either IV paclitaxel 135 mg/m 2 over 24 hours followed by IV cisplatin 75 mg/m 2 every 3 weeks for six courses or IV carboplatin (area under curve 9) every 28 days for two courses, then IV paclitaxel 135 mg/m 2 over 24 hours followed by intraperitoneal (IP) cisplatin 100 mg/m 2 every 3 weeks for six courses. RESULTS: Of the 523 patients who entered this trial, 462 were determined to be assessable, with prognostic factors well balanced between the treatments. Neutropenia, thrombocytopenia, and gastrointestinal and metabolic toxicities were greater in the experimental arm. As a result, 18% of the patients received ≤ two courses of IP therapy. Progression-free survival was superior for patients randomized to the experimental treatment arm (median, 28 v 22 months; relative risk, 0.78; log-rank P = .01, one-tail). There was a borderline improvement in overall survival associated with this regimen (median, 63 v 52 months; relative risk, 0.81; P = .05, one-tail). CONCLUSION: An experimental regimen including moderately high-dose IV carboplatin followed by IP paclitaxel and IV cisplatin yielded a significant improvement in progression-free survival when compared with a standard regimen of IV cisplatin and paclitaxel. Because the improvement in overall survival was of borderline statistical significance and toxicity was greater, the experimental arm is not recommended for routine use. However, the results provide direction for further clinical investigation in small-volume ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1748 · Cited by 1,866
Alberts, D. S., Liu, P. Y., Hannigan, E. V., O'Toole, R., Williams, S. D., Young, J. A., Franklin, E. W., Clarke-Pearson, D. L., Malviya, V. K., DuBeshter, B., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352603 · Cited by 1,228
Self-citationSample-Size Formula for the Proportional-Hazards Regression Model
Schoenfeld, D. A. (1983) · Biometrics · doi:10.2307/2531021 · Cited by 1,096
Piccart, M. J. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.9.699 · Cited by 981
Creatinine Clearance: Bedside Estimate
JELLIFFE, R. W. (1973) · Annals of Internal Medicine · doi:10.7326/0003-4819-79-4-604 · Cited by 489
Cited by
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Self-citationA Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Cannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
Lheureux, S., Gourley, C., Vergote, I., & Oza, A. M. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32552-2 · Cited by 1,919
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Lheureux, S., Braunstein, M., & Oza, A. M. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21559 · Cited by 1,423
Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz062 · Cited by 1,197
Treatment of epithelial ovarian cancer
Kuroki, L., & Guntupalli, S. R. (2020) · BMJ · doi:10.1136/bmj.m3773 · Cited by 873
Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study
Winter, W. E., Maxwell, G. L., Tian, C., Carlson, J. W., Ozols, R. F., Rose, P. G., Markman, M., Armstrong, D. K., Muggia, F., & McGuire, W. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2517 · Cited by 845
Self-citationRecent progress in the diagnosis and treatment of ovarian cancer
Jelovac, D., & Armstrong, D. K. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20113 · Cited by 765
High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
Lisio, M.-A., Fu, L., Goyeneche, A., Gao, Z.-H., & Telleria, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040952 · Cited by 680
Hennessy, B. T., Coleman, R. L., & Markman, M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61338-6 · Cited by 640
Self-citationHyperthermia adds to chemotherapy
Issels, R. D. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.07.038 · Cited by 545
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
Berek, J. S., Renz, M., Kehoe, S., Kumar, L., & Friedlander, M. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13878 · Cited by 514
A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer
Bonome, T., Levine, D. A., Shih, J., Randonovich, M., Pise-Masison, C. A., Bogomolniy, F., Ozbun, L., Brady, J., Barrett, J. C., Boyd, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6595 · Cited by 439
Chang, S.-J., Hodeib, M., Chang, J., & Bristow, R. E. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.05.040 · Cited by 433
Wright, A. A., Bohlke, K., Armstrong, D. K., Bookman, M. A., Cliby, W. A., Coleman, R. L., Dizon, D. S., Kash, J. J., Meyer, L. A., Moore, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.6907 · Cited by 409
Colombo, N., Sessa, C., Bois, A. D., Ledermann, J., McCluggage, W., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000308 · Cited by 407
Optimal primary surgical treatment for advanced epithelial ovarian cancer
Elattar, A., Bryant, A., Winter-Roach, B. A., Hatem, M., & Naik, R. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007565.pub2 · Cited by 403
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
Kampan, N. C., Madondo, M. T., McNally, O. M., Quinn, M., & Plebanski, M. (2015) · BioMed Research International · doi:10.1155/2015/413076 · Cited by 362
Wright, A. A., Bohlke, K., Armstrong, D. K., Bookman, M. A., Cliby, W. A., Coleman, R. L., Dizon, D. S., Kash, J. J., Meyer, L. A., Moore, K. N., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.05.022 · Cited by 362
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
Jaaback, K., Johnson, N., & Lawrie, T. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005340.pub4 · Cited by 359
Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications
Alyami, M., Hübner, M., Grass, F., Bakrin, N., Villeneuve, L., Laplace, N., Passot, G., Glehen, O., & Kepenekian, V. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30318-3 · Cited by 331
Cancer of the ovary, fallopian tube, and peritoneum
Berek, J. S., Kehoe, S. T., Kumar, L., & Friedlander, M. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12614 · Cited by 327
Diagnosis and Treatment of Ovarian Cancer
Orr, B., & Edwards, R. P. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.07.010 · Cited by 322
Cancer of the ovary, fallopian tube, and peritoneum
Berek, J. S., Crum, C., & Friedlander, M. (2012) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(12)60025-3 · Cited by 322
Epithelial Ovarian Cancer: A Review of Current Management
Guppy, A. E., Nathan, P. D., & Rustin, G. J. S. (2005) · Clinical Oncology · doi:10.1016/j.clon.2005.05.009 · Cited by 311
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., Berek, J. S., Chen, L.-M., Cristea, M., DeRosa, M., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0039 · Cited by 309
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Helm, C. W., Richard, S. D., Pan, J., Bartlett, D., Goodman, M. D., Hoefer, R., Lentz, S. S., Levine, E. A., Loggie, B. W., Metzinger, D. S., et al. (2010) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181c50cde · Cited by 302
Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary
Gershenson, D. M., Sun, C. C., Lu, K. H., Coleman, R. L., Sood, A. K., Malpica, A., Deavers, M. T., Silva, E. G., & Bodurka, D. C. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000227787.24587.d1 · Cited by 290
Tewari, D., Java, J. J., Salani, R., Armstrong, D. K., Markman, M., Herzog, T., Monk, B. J., & Chan, J. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9898 · Cited by 288
Self-citationMinireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy
Romero, I., & Bast, R. C. (2012) · Endocrinology · doi:10.1210/en.2011-2123 · Cited by 286
Chemotherapy Resistance in Advanced Ovarian Cancer Patients
Pokhriyal, R., Hariprasad, R., Kumar, L., & Hariprasad, G. (2019) · Biomarkers in Cancer · doi:10.1177/1179299x19860815 · Cited by 283
Bakrin, N., Bereder, J. M., Decullier, E., Classe, J. M., Msika, S., Lorimier, G., Abboud, K., Meeus, P., Ferron, G., Quenet, F., et al. (2013) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2013.09.030 · Cited by 272
Berchuck, A., Iversen, E. S., Lancaster, J. M., Pittman, J., Luo, J., Lee, P., Murphy, S., Dressman, H. K., Febbo, P. G., West, M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2398 · Cited by 266
Wenzel, L. B., Huang, H. Q., Armstrong, D. K., Walker, J. L., & Cella, D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3494 · Cited by 197
Systemic Therapy for Ovarian Cancer: Current Status and New Treatments
Ozols, R. F. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.03.011 · Cited by 188
Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer
Wright, A. A., Cronin, A., Milne, D. E., Bookman, M. A., Burger, R. A., Cohn, D. E., Cristea, M. C., Griggs, J. J., Keating, N. L., Levenback, C. F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.4776 · Cited by 185
Shahid, F., Farooqui, Z., & Khan, F. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.03.009 · Cited by 166
Intraperitoneal Therapy for Peritoneal Cancer
Lu, Z., Wang, J., Wientjes, M. G., & Au, J. L.-S. (2010) · Future Oncology · doi:10.2217/fon.10.100 · Cited by 160
Hartmann, L. C., Lu, K. H., Linette, G. P., Cliby, W. A., Kalli, K. R., Gershenson, D., Bast, R. C., Stec, J., Iartchouk, N., Smith, D. I., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1673 · Cited by 141
“from the literature for patients with optimally debulked advanced-stage disease treated with platinum-paclitaxel (5, 21).”
BackgroundHeated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer
Jewell, A., McMahon, M., & Khabele, D. (2018) · Cancers · doi:10.3390/cancers10090296 · Cited by 24
Current First-line Therapy for Ovarian Cancer: A Comprehensive Review
Pierce, S. R., & Clark, L. H. (2018) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000613 · Cited by 17
Skaznik-Wikiel, M. E., Lesnock, J. L., McBee, W. C., Beriwal, S., Zorn, K. K., Richard, S. D., Krivak, T. C., & Edwards, R. P. (2012) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e318234f833 · Cited by 15
“05).(4) Finally, Armstrong et al(5) reported significant improvements in both PFS and OS in patients treated with IP cisplatin and 24 hour infusion of paclitaxel.”
Background
Metadata
- Authors
- Markman, M., Bundy, B. N., Alberts, D. S., Fowler, J. M., Clark-Pearson, D. L., Carson, L. F., Wadler, S., & Sickel, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-02-15
- Volume
- 19
- Issue
- 4
- Pages
- 1001-1007
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1922469696
- Cited by
- 1,080
- References
- 18
- FWCI
- 24.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.